Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis
Li et al.,
Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis,
Research Square, doi:10.21203/rs.3.rs-119202/v1 (Preprint)
Small retrospective database analysis of 37 late stage patients hospitalized in an intensive care center in China, not finding a significant difference in viral shedding. Pateints were all in serious condition. There was only one death however the group is not specified.
Confounding by indication is likely.
time to viral-, 40.0% higher, relative time 1.40, p = 0.06, treatment 18, control 19.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Li et al., 12 Jan 2021, retrospective, database analysis, China, preprint, 5 authors.
Abstract: Treatment of COVID-19 patients with
hydroxychloroquine or chloroquine: A retrospective
analysis
Hui Li
Hangzhou Red Cross Hospital
Min Deng
Hangzhou Red Cross Hospital
Jie Wang
Hangzhou Red Cross Hospital
Lin Ma
Hangzhou Red Cross Hospital
Zheng Yang ( 201411121611441@zcmu.edu.cn )
Hangzhou Red Cross Hospital
Research Article
Keywords: SARS-CoV-2, COVID-19, Hydroxychloroquine, Chloroquine
Posted Date: January 12th, 2021
DOI: https://doi.org/10.21203/rs.3.rs-119202/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Blinded Manuscript
Background
There is an urgent need for an effective treatment to cure patients with COVID-19 and
reduce the duration of viral shedding.
Methods
We conducted a retrospective study using data from the electronic medical records of
patients with confirmed SARS-CoV-2 infection who were hospitalized in the E1-4
intensive care center of Guanggu Hospital, Wuhan City, Hubei Province, China, from
February 11, 2020, to March 23, 2020. According to the diagnostic results, the
hospitalized patients were divided into the experimental group treated with
hydroxychloroquine (HCQ) or chloroquine (CQ) and the control group only treated
with conventional therapy without HCQ or CQ. The main outcome was the clearance
rate of SARS-CoV-2.
Results
A total of 37 patients were evaluated. Eighteen patients were assigned to the HCQ or
CQ group, and 19 were assigned to the routine treatment group. Treatment with HCQ or
CQ was not associated with a difference from routine treatment in the viral shedding
duration (median, 14 days vs. 10 days; hazard ratio for viral shedding, 0.393; 95%
confidence interval [CI], 0.151 to 1.022; P=0.056). No significant difference in the viral
shedding rate was observed between the groups at any time point (7 days, 14 days, 21
days, 28 days and the end point).
Conclusion
Although this is a retrospective analysis, the results suggest that treatment with HCQ
or CQ had no impact on the duration of viral shedding.
Keywords: SARS-CoV-2, COVID-19, Hydroxychloroquine, Chloroquine
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit